extract: 2026-02-01-glp1-patent-cliff-generics-global-competition

Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -119,6 +119,18 @@ International generic competition beginning January 2026 (Canada patent expiry,
 
 If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), and if behavioral change persists after medication discontinuation, then the chronic use model may not be necessary for long-term value capture. This challenges the inflationary cost projection if the optimal intervention is time-limited medication + permanent behavioral change rather than lifetime pharmacotherapy.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-19*
+
+International generic competition beginning in 2026 will compress prices far faster than the 'inflationary through 2035' timeline assumes. Canada's semaglutide patents expired January 4, 2026, with Sandoz, Apotex, and Teva filing immediately. Brazil opens to generics March 2026. China has 17+ Phase 3 generic candidates targeting $40-$50/month pricing. India patents expire March 2026. Even with US patents extending to 2031-2032, international price arbitrage and compounding pharmacy pressure will drive US prices below $100/month by 2030. At $50-100/month, GLP-1s become unambiguously cost-effective under any payment model, fundamentally changing the cost trajectory from inflationary to cost-saving much earlier than 2035.
+
+
+### Additional Evidence (extend)
+*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-19*
+
+Oral Wegovy launched January 2026 at $149-$299/month with Medicare deal at $245/month, representing 75-85% price compression from injectable formulations. Orforglipron (Eli Lilly non-peptide oral GLP-1) could be approved Q2 2026, adding competitive pressure. The price trajectory is steeper than the chronic-use-inflation model anticipated: oral formulations are already approaching the cost-effectiveness threshold before generics arrive.
+
 ---
 
 Relevant Notes:

inbox/queue/2026-02-01-glp1-patent-cliff-generics-global-competition.md

@@ -7,9 +7,13 @@ date: 2026-02-01
 domain: health
 secondary_domains: [internet-finance]
 format: article
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure]
+processed_by: vida
+processed_date: 2026-03-19
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -50,3 +54,15 @@ Overview of the GLP-1 generic competition landscape as patents begin expiring in
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong
 EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure
+
+
+## Key Facts
+- Semaglutide patents extend to 2031-2032 in US and Europe
+- Canada's semaglutide patents expired January 4, 2026
+- Brazil generic competition opens March 2026
+- India semaglutide patents expire March 2026
+- China has 17+ generic semaglutide candidates in Phase 3 trials
+- Oral Wegovy launched January 2026 at $149-$299/month
+- Medicare oral Wegovy deal: $245/month
+- Orforglipron (Lilly) potential approval Q2 2026
+- Amycretin shows 22% weight loss without plateau